This retrospective study included nAMD patients whose eyes were grouped into the following cohorts, with the overall cohort receiving ≥ 1 brolucizumab injection; the 12-month and 18-month brolucizumab (BRO) cohorts, which consisted of nAMD patient eyes who switched from a previous anti-vascular endothelial growth factor (VEGF) and had ≥3 brolucizumab injections with no other anti-VEGF in the first 12 months (360 days) and 18 months (540 days) of follow-up respectively; and the 12-month and 18-month alternating (ALT) cohorts, which consisted of nAMD patient eyes who switched from a previous anti-VEGF to brolucizumab and had ≥2 brolucizumab injections and ≥1 injection of another anti-VEGF in the first 12 months and 18 months of follow-up, respectively.
Study Type
OBSERVATIONAL
Enrollment
414
Novartis
East Hanover, New Jersey, United States
Mean change in injection interval from baseline to Month 12 for BRO and ALT cohorts
Time frame: Baseline, Month 12
Change in injection interval from first brolucizumab injection to Month 18 for BRO and ALT cohorts
Time frame: Baseline, Month 18
Change in visual acuity (VA) from first brolucizumab injection to Month 12 (for BRO and ALT cohorts) and Month 18 (for BRO cohort)
Time frame: Baseline, Months 12 and 18
Change in central macular thickness (CMT) from first brolucizumab injection to Month 12 (for BRO and ALT cohorts) and Month 18 (for BRO cohort)
Time frame: Baseline, Months 12 and 18
Age
Time frame: Baseline
Gender
Time frame: Baseline
Visual acuity (Early Treatment Diabetic Retinopathy Study [ETDRS] Letters)
Time frame: Baseline, Month 12 and Month 18
Anti-VEGF treatment status
Time frame: Baseline
Last injection interval before switch to brolucizumab in prior-treated eyes
Time frame: Baseline
Central macular thickness (CMT)
Time frame: Baseline, Month 12 and Month 18
Intraretinal fluid (IRF)
Time frame: Baseline
Subretinal fluid (SRF)
Time frame: Baseline
Pigment epithelial detachment (PED)
Time frame: Baseline
Number of brolucizumab injections and non-brolucizumab injections from first brolucizumab injection to 12 months (for ALT cohort)
Time frame: Baseline, Month 12
Ocular adverse events (AEs) in eyes treated with at least one brolucizumab injection
Time frame: Up to 3 years
Median time (days) from first brolucizumab injection to AE
Time frame: Up to 3 years
Median time (days) from last brolucizumab injection pre-AE to AE
Time frame: Up to 3 years
Median time (days) from AE to resolution
Time frame: Up to 3 years
Median number of brolucizumab injections pre-AE including the index injection
Time frame: Up to 3 years
Proportion of patients in different levels of vision recovery after AE resolution
Time frame: Up to 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.